269 related articles for article (PubMed ID: 34344244)
21. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification].
Zhu MX; Wan WL; Li HS; Wang YF; Wang J; Ling HS; Yan XX; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1427-1432. PubMed ID: 27784369
[TBL] [Abstract][Full Text] [Related]
24. Four-color flow cytometric analysis of myeloma plasma cells.
Kobayashi S; Hyo R; Amitani Y; Tanaka M; Hashimoto C; Sakai R; Tamura T; Motomura S; Maruta A
Am J Clin Pathol; 2006 Dec; 126(6):908-15. PubMed ID: 17153775
[TBL] [Abstract][Full Text] [Related]
25. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
[TBL] [Abstract][Full Text] [Related]
26. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma.
Pozdnyakova O; Morgan EA; Li B; Shahsafaei A; Dorfman DM
Leuk Lymphoma; 2012 Oct; 53(10):1905-10. PubMed ID: 22423624
[TBL] [Abstract][Full Text] [Related]
27. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
29. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.
Jeong TD; Park CJ; Shim H; Jang S; Chi HS; Yoon DH; Kim DY; Lee JH; Lee JH; Suh C; Lee KH
Korean J Hematol; 2012 Dec; 47(4):260-6. PubMed ID: 23320004
[TBL] [Abstract][Full Text] [Related]
30. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
31. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
34. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset.
Hayhoe RP; Henson SM; Akbar AN; Palmer DB
Hum Immunol; 2010 Jul; 71(7):676-81. PubMed ID: 20394788
[TBL] [Abstract][Full Text] [Related]
35. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
36. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.
Pellat-Deceunynck C; Barillé S; Puthier D; Rapp MJ; Harousseau JL; Bataille R; Amiot M
Cancer Res; 1995 Aug; 55(16):3647-53. PubMed ID: 7543019
[TBL] [Abstract][Full Text] [Related]
37. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
[TBL] [Abstract][Full Text] [Related]
38. Combined CD25, CD64, and CD69 biomarker panel for flow cytometry diagnosis of sepsis.
Zhou Y; Zhang Y; Johnson A; Venable A; Griswold J; Pappas D
Talanta; 2019 Jan; 191():216-221. PubMed ID: 30262053
[TBL] [Abstract][Full Text] [Related]
39. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells.
Drach J; Gattringer C; Huber H
Clin Exp Immunol; 1991 Mar; 83(3):418-22. PubMed ID: 1706237
[TBL] [Abstract][Full Text] [Related]
40. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
